What Are Papillary Muscles and How Do They Work?

Papillary muscles are small, finger-like projections of heart muscle that rise from the inner walls of the ventricles and anchor the valve leaflets in place through thin cords called chordae tendineae. Their central job is to prevent the mitral and tricuspid valves from blowing backward into the atria when the ventricles contract, and when they fail, the consequences can range from a chronic leaking valve to sudden cardiogenic shock. Despite their small size, these structures sit at the intersection of several major cardiac problems, from heart attacks to inherited heart disease to dangerous rhythm disturbances.

Where They Are and What They Look Like

The left and right ventricles each have their own set of papillary muscles, and the two sets differ in number, size, and shape. In the left ventricle, where the mitral valve lives, you typically find two groups: an anterolateral papillary muscle and a posteromedial one. The most common arrangement is a single anterolateral muscle and two posteromedial muscles, though the pattern varies considerably from person to person. In the right ventricle, which houses the tricuspid valve, the classic textbook picture of three distinct papillary muscles (anterior, posterior, and septal) appears in only about a quarter of hearts. The anterior muscle is almost always present, but the septal muscle is absent more than half the time in some study populations.

Shape varies too. The most commonly observed forms are conical and flat-topped, though muscles can also appear bifid (split at the tip) or have irregular surfaces. The anterior papillary muscle tends to be the largest in both ventricles. In the right ventricle, it averages roughly 2 cm long and under 1 cm wide, while in the left ventricle, papillary muscles are generally longer than their right-sided counterparts.¹ This variability matters to surgeons, who cannot assume a standard anatomy when operating on a valve.²

How They Keep the Valves Working

During every heartbeat, the ventricles squeeze forcefully to push blood into the lungs and body. That squeezing generates enormous pressure inside the chamber, and without restraint, the thin valve leaflets would flip inside out and allow blood to rush backward. The papillary muscles prevent this by contracting in sync with the ventricular wall, pulling the chordae tendineae taut and holding the leaflets in a closed position. They do not actually pull the valve shut; the pressure difference does that. What the papillary muscles do is brace the leaflets so they stay shut under pressure.³

This means that anything disrupting the position, timing, or integrity of the papillary muscles can cause the valve to leak. Even a small shift in where a papillary muscle sits relative to the leaflet it supports can change the geometry enough to allow regurgitation, which is blood flowing the wrong way through the valve.

Blood Supply and a Built-In Vulnerability

The papillary muscles get their blood from the coronary arteries, but not all papillary muscles enjoy the same level of supply. In the left ventricle, the anterolateral papillary muscle usually receives blood from two separate coronary branches, giving it a backup if one is blocked. The posteromedial papillary muscle, by contrast, is fed by a single vessel in roughly two-thirds of people, typically a branch of the right coronary artery.⁴ That single-vessel dependency makes the posteromedial muscle far more vulnerable during a heart attack. If its sole feeding artery gets blocked, the entire muscle loses blood flow with no alternative route to pick up the slack.

Interestingly, studies comparing the small arteries within papillary muscles across humans, dogs, sheep, and goats found no statistically significant differences in vessel wall thickness. The arteries thin out from the base to the tip of the muscle in all species, which means the tip is inherently the most ischemia-prone zone regardless of species.⁵

When a Heart Attack Damages the Papillary Muscles

Papillary muscle damage after a heart attack falls on a spectrum, from mild dysfunction that causes a modest valve leak all the way to outright rupture, which is a surgical emergency. The underlying problem in the chronic form is not usually that the muscle itself dies but that the surrounding ventricular wall remodels and dilates after the infarction. As the wall bulges outward, it drags the papillary muscle with it, pulling it away from the valve leaflet. The leaflet then gets tethered in an abnormal position and cannot close properly.⁶ Animal studies confirm that posterolateral displacement of the posteromedial papillary muscle is the main driver of this leaflet tethering and subsequent mitral regurgitation.⁷

This chronic ischemic mitral regurgitation can develop gradually over weeks to months after a heart attack and contributes to heart failure symptoms: shortness of breath, fluid retention, and exercise intolerance. It is one of the reasons post-heart-attack patients are monitored with echocardiography even after the acute crisis has passed.

Papillary Muscle Rupture

Rupture is the catastrophic end of the spectrum. It typically occurs within the first week after a heart attack, often around days three through seven, when the infarcted tissue is at its weakest. The posteromedial papillary muscle ruptures far more often than the anterolateral, directly reflecting its more precarious single-vessel blood supply.⁸ When a papillary muscle or one of its heads tears loose, the valve leaflet it was holding suddenly flails freely, and blood pours backward with every heartbeat. The result is acute, severe mitral regurgitation.

Clinically, this looks dramatic. A patient who had been recovering from their heart attack suddenly develops chest pain, plummeting blood pressure, and flash pulmonary edema as blood backs up into the lungs.⁹ Anterolateral rupture, though rarer, produces the same picture of torrential mitral regurgitation and cardiogenic shock, and it can occur even when the left ventricle is squeezing normally.¹⁰ Emergency surgery to repair or replace the valve is usually the only option, and even with surgery, the mortality rate is high because these patients are already in shock.

The Role in Hypertrophic Cardiomyopathy

Papillary muscles are not just passive victims of coronary artery disease. In hypertrophic cardiomyopathy, an inherited condition in which the heart muscle grows abnormally thick, the papillary muscles themselves can be part of the problem. Patients with this condition frequently show abnormal papillary muscle anatomy: they are more likely to have a double bifid (split-headed) papillary muscle, and the anterolateral papillary muscle tends to sit in an abnormally forward and upward position. In one study, double bifid papillary muscles appeared in about 70% of hypertrophic cardiomyopathy patients compared with 17% of controls, and anteroapical displacement of the anterolateral muscle appeared in 77% versus 17%.¹¹

These anatomical quirks are not cosmetic. They physically push the mitral valve leaflet into the outflow tract during contraction, contributing to the obstruction that is the hallmark of the disease. Patients with anteroapically displaced papillary muscles had an odds ratio of about 7 for having a significant resting outflow-tract gradient, and those with double bifid muscles had an odds ratio of about 10, independent of how thick the septum was or what medications the patients were on. This has changed how cardiologists think about obstruction in hypertrophic cardiomyopathy: it is not only a problem of a thick septum but also of misplaced papillary muscles pulling the valve into the wrong spot.

Newer imaging techniques can measure how well papillary muscles are contracting by tracking their deformation, or strain. In patients with hypertrophic cardiomyopathy, the strain values of both the anterolateral and posteromedial papillary muscles are significantly reduced compared with patients who simply have high-blood-pressure-related thickening. Cutoff values around –15% to –17% can help distinguish the two conditions with moderate sensitivity and good specificity, which is useful because the treatment strategies differ considerably.¹²

Papillary Muscles as a Source of Abnormal Heart Rhythms

Papillary muscles can also be the origin of ventricular arrhythmias, including premature ventricular complexes (extra beats) and ventricular tachycardia (runs of fast, abnormal rhythm). These arrhythmias tend to arise from the tip of the papillary muscle: about two-thirds of ectopic foci sit in the distal third, with smaller proportions in the middle and base.¹³ The characteristic electrocardiogram patterns can sometimes point clinicians toward a papillary muscle origin before any invasive mapping is done, which helps plan treatment.

Catheter ablation, the procedure in which a thin wire is threaded into the heart to burn away the tissue causing the arrhythmia, can cure these rhythms. But papillary muscle ablations are notoriously difficult. The muscles move with every heartbeat, making it hard to keep the catheter tip stable against the tissue. The arrhythmia’s exit point can shift during the procedure because of the complex fiber architecture within the muscle. Some centers have responded by ablating all the way around the base of the papillary muscle to isolate the abnormal focus rather than trying to target it precisely.¹⁴ Cryoablation, which freezes tissue instead of burning it, can be a useful alternative because the catheter tip adheres to the tissue once frozen, solving the stability problem.¹⁵ Real-time intracardiac echocardiography, which uses a tiny ultrasound probe inside the heart itself, has become the go-to imaging tool during these procedures to see exactly where the catheter is relative to the moving muscle.¹⁶

Seeing Papillary Muscle Damage on Imaging

Cardiac MRI with a technique called late gadolinium enhancement has become the gold standard for detecting papillary muscle infarction. The gadolinium contrast agent washes out of healthy muscle but lingers in scarred or infarcted tissue, making damaged papillary muscles light up on the scan. Among patients with ST-elevation heart attacks, about 40% show papillary muscle enhancement, and the posterior muscle is involved far more often than the anterior one (roughly 77% versus 26% of those with enhancement).¹⁷

Standard late gadolinium imaging can miss subtler papillary muscle scarring because the small muscles are surrounded by bright blood pool, which makes contrast-enhanced tissue harder to spot. A newer combined bright-and-black-blood MRI technique significantly improves detection, raising sensitivity from about 61–82% to 89–100% depending on the reader, and improving reproducibility between observers.¹⁸ Automated detection algorithms built on this dual-contrast approach have reached about 87% sensitivity, which hints at a future in which papillary muscle damage gets flagged routinely during post-heart-attack imaging rather than only when a radiologist specifically looks for it.

In patients with mitral valve prolapse, papillary muscle enhancement carries a different clinical significance. It can be a marker for dangerous arrhythmias. In one series, papillary muscle enhancement was found in about 8% of patients overall with mitral regurgitation, and among those with mitral valve prolapse specifically, one patient with diffuse papillary muscle enhancement experienced sudden cardiac arrest from ventricular fibrillation. Ventricular arrhythmia had an odds ratio of nearly 7 for predicting papillary muscle enhancement in that study.¹⁹

Congenital Anomalies Involving Papillary Muscles

Some people are born with papillary muscle arrangements that cause problems from infancy. The best-known congenital variant is the parachute mitral valve, in which all the chordae insert into a single papillary muscle instead of the usual two groups. The resulting valve opens through a restricted, funnel-like orifice and can cause significant obstruction to blood flow entering the left ventricle. A true single-papillary-muscle parachute valve is actually quite rare. Far more common is what is called a parachute-like asymmetric mitral valve, in which two papillary muscles exist but one is abnormally elongated and positioned high in the ventricle, with its tip reaching almost to the valve ring. That abnormal muscle draws most or all of the chordae to itself, creating an off-center opening.²⁰ These asymmetric papillary muscles frequently occur alongside other congenital heart defects, which makes preoperative imaging critical for surgical planning.²¹

Surgical Techniques That Reposition Papillary Muscles

When ischemic mitral regurgitation persists despite medical therapy and the valve itself is structurally normal, the problem is geometry: the papillary muscle has been displaced by ventricular remodeling, and the leaflet cannot close. Traditional surgery addresses this by placing a ring around the valve annulus to cinch it smaller, but that does not fix the underlying tethering. A more targeted approach physically relocates the papillary muscle back toward the valve. Surgeons pass sutures through the posteromedial papillary muscle and anchor them to the fibrous ring at the base of the anterior leaflet, effectively pulling the muscle forward and inward to a more natural position.²² This technique is often combined with coronary bypass surgery and annuloplasty ring placement.

The challenge has always been deciding exactly how far to relocate the muscle. Pull it too much and you risk distorting the valve in a new way; not enough and the regurgitation persists. Recent work has introduced formula-based approaches that use preoperative measurements to calculate the precise distance the suture should travel from the papillary muscle to the annular ring, standardizing a procedure that was previously done largely by feel.²³

How Papillary Muscles Form Before Birth

Papillary muscles are not separate structures that get grafted onto the heart during development. They emerge from the ventricular wall itself. Early in embryonic life, a horseshoe-shaped ridge of muscle runs along the interior of the developing left ventricle, from the anterior wall through the apex to the posterior wall. As the heart grows, the front and back portions of this ridge enlarge, gradually separate from the overlying atrial muscle, and peel away from the ventricular wall. The bridge connecting them gets absorbed into the mesh of tiny muscle strands lining the ventricle. What remains are the anterolateral and posteromedial papillary muscles, each now free-standing pillars connected to the valve above by chordae.²⁴

Understanding this developmental process explains why congenital papillary muscle anomalies like the parachute valve occur. If the normal delamination process stalls or one portion of the horseshoe ridge fails to separate properly, you can end up with a single dominant muscle or with one muscle that never fully detaches from the wall. The embryology maps directly onto the surgical anatomy, which is one reason pediatric heart surgeons pay close attention to this developmental biology when planning repairs on infant hearts.

The Nitric Oxide Connection

Beyond their mechanical role, papillary muscles respond to the same chemical signals that influence heart muscle contractility everywhere else, sometimes in surprising ways. Nitric oxide, a molecule the body uses to relax blood vessels and modulate cardiac function, has a dose-dependent and context-dependent effect on papillary muscle force. At low levels of sympathetic stimulation, nitric oxide actually boosts the force a papillary muscle generates. But at high levels of stimulation, nitric oxide flips and reduces force instead. In laboratory experiments on mammalian papillary muscles, a nitric oxide donor increased developed force by about 10–11% when a low-dose adrenaline-like drug was also present, but when the same muscles were pushed with a high dose of the stimulant, nitric oxide decreased force instead.²⁵ This bidirectional effect is thought to arise from crosstalk between different signaling pathways inside the muscle cell. Clinically, it adds nuance to any therapeutic strategy involving nitric oxide donors or drugs that influence its levels, particularly in heart failure patients whose sympathetic nervous system is already in overdrive.